Investigation Report on China Linezolid Market, 2010-2019 is a new market research publication announced by Reportstack. Infection caused by bacteria that are resistant to antibiotics is spreading over the world with increasing infection rate and mortality rate, which has posed a serious threat to human health. In 2004, National Nosocomial Infection Surveillance reported that people infected by Methicillin Resistant Staphylococcus Aureus (MRSA) take up 63.3% of all patients with nosocomial infection of staphylococcus aureus. Among staphylococcus aureus infections, MRSA separation rate occupied 69.2%. The mortality rate of MRSA infection is 20 times of Methicillin Sensitive Staphylococcus Aureus (MSSA).
Linezolid, a synthetic oxazolidinone, was developed by Pharmacia & Upjohn. In 2000, it was approved by FDA to be used for infection caused by gram-positive coccus, including suspected or confirmed Hospital Acquired Pneumonia (HAP) caused by MRSA, Community Acquired Pneumonia (CAP), skin and soft tissue infections (SSTI) and vancomycin-resistant enterococcus infection. Linezolid brought in sales revenue of USD 150 million in the same year it entered market and its sales in the global market during the period of 2013-2014 reached up to USD 1350 million. In China, linezolid market has long been monopolized by foreign pharmaceutical corporations. Since the patent for linezolid’s crystal form shall expire in 2021, its price stays high.
To view the table of contents and know more details please visit Investigation Report on China Linezolid Market, 2010-2019
Linezolid develops fast after entering China. In recent years, its sales value in the Chinese market has been extremely unstable, falling from CNY 113 million in 2010 to CNY 93 million in 2014. Currently, linezolid in the Chinese market comes from the following three companies: Pfizer Inc., Fresenius Kabi and Pharmacia & Upjohn, among which Pfizer has the largest market share of 69.92% with sales in 2014 reaching up to CNY 64.24 million.
Generally speaking, linezolid enjoys a vast demand in China.
Readers can get at least the following information through this report:
-market size of linezolid in China
-major manufacturers of linezolid in the Chinese market and their market share
-retail price of linezolid in China
-market outlook of linezolid in China
The author suggests the following groups of people purchase this report:
-manufacturers of anti-infectious agents
-investors/ research institutions interested in Chinese medicine market
-any interest in Chinese medicine market
Companies Mentioned
Pfizer Inc. (the US); Fresenius Kabi; Pharmacia & Upjohn
About Reportstack:
Reportstack is one of the leading distributors of market research reports in the world today. We host more than 200,000 research products from the world’s top publication houses. These publications are distributed amongst 12 top industry verticals and 62 sub verticals, which are then further classified into 257 business categories and 5000 micro markets. The vast selection criterion provides granular data from the length and breadth of all these industries delivering Reportstack members with cutting edge research products to facilitate strategic business decisions.
Contact:
Debora White
Manager – Marketing
debora@reportstack.com
Ph: +1-888-789-6604
Reportstack Market Research
Market Research Reports on Chinese Industry 